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Aim: To derive and validate a set of computational models able to assess the risk of developing complications
and experiencing adverse events for patients with diabetes. The models are developed on data from the
Diabetes Control and Complications Trial (DCCT) and the Epidemiology of Diabetes Interventions and
Complications (EDIC) studies, and are validated on an external, retrospectively collected cohort.
Methods: We selected ﬁfty-one clinical parameters measured at baseline during the DCCT as potential risk
factors for the following adverse outcomes: Cardiovascular Diseases (CVD), Hypoglycemia, Ketoacidosis,
Microalbuminuria, Proteinuria, Neuropathy and Retinopathy. For each outcome we applied a data-mining
analysis protocol in order to identify the best-performing signature, i.e., the smallest set of clinical parameters
that, considered jointly, are maximally predictive for the selected outcome. The predictive models built on the
selected signatures underwent both an interval validation on the DCCT/EDIC data and an external validation on
a retrospective cohort of 393 diabetes patients (49 Type I and 344 Type II) from the Chorleywood Medical
Center, UK.
Results: The selected predictive signatures contain ﬁve to ﬁfteen risk factors, depending on the speciﬁc
outcome. Internal validation performances, as measured by the Concordance Index (CI), range from 0.62 to
0.83, indicating good predictive power. The models achieved comparable performances for the Type I and,
quite surprisingly, Type II external cohort.
Conclusions: Data-mining analyses of the DCCT/EDIC data allow the identiﬁcation of accurate predictive
models for diabetes-related complications. We also present initial evidences that these models can be applied
on a more recent, European population.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Computational models for assessing the risk of diabetes-related
complications are becoming more and more prevalent in diabetes
clinical research (Palmer, 2013). Risk assessment models can be
deﬁned as mathematical tools that evaluate the risk of experiencing
an adverse outcome on the basis of patient’s clinical proﬁle. These
models are employed in clinical practice for assisting the clinicians in
stratifying patients according to the gravity of their conditions and the
possible evolution of their clinical trajectories. Moreover, devising risk
assessment models usually leads to the identiﬁcation of novel riskare no conﬂicts of interest.
n, GR-700 13 Heraklion, Crete,
Inc. This is an open access article ufactors associated with a given complications. In turn, this knowledge
potentially grants a better understanding of diabetes pathophysiology
(Ajmera, Swat, Laibe, Le, & Chelliah, 2013).
We analyzed the information collected during the Diabetes and
Complication Control Trial (DCCT) (The Diabetes Control and
Complications Trial Research Group, 1993) and the Epidemiology of
Diabetes Interventions and Complications study (EDIC) (Nathan et al.,
2005) for deriving risk assessment models for seven different
diabetes-related complications and adverse events: Cardiovascular
Diseases (CVD), Hypoglycemia, Ketoacidosis, Microalbuminuria, Pro-
teinuria, Neuropathy and Retinopathy. Particularly, for each compli-
cation we tried to identify the minimal set of clinical parameters that,
considered jointly, are maximally predictive. Identifying such minimal
sets of risk factors leads to models easier to interpret, possibly
providing intuitions into the mechanisms originating the disease,
while discarded factors are either irrelevant or redundant givennder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nomic research (Subramanian & Simon, 2010), hereafter we will
refer to such parsimonious, predictive sets of risk factors as pre-
dictive signatures.
During our analyses we employed a complex machine-learning
protocol (Lagani & Tsamardinos, 2010) in order to simultaneously (a)
identify the predictive signatures, (b) derive the best models over the
selected signatures and (c) unbiasedly assess the performances of the
models on the DCCT/EDIC data (internal validation). Moreover, we
retrospectively collected data from 393 Type I (49) and Type II (344)
diabetes patients, followed in the ChorleywoodMedical Center (CHC),
United Kingdom (UK), in the period 2004–2014. The models were
evaluated on this external cohort, in order to assess their transfer-
ability on a population with different characteristics with respect to
the one followed in the DCCT/EDIC study.
The results of the validation indicate that models trained on a USA/
Canada cohort of diabetes patients enrolled in the 80’s can actually
transfer on a cohort of contemporary European patients. Transfer-
ability increases when the models are re-calibrated on the new data
by conserving the original predictive signature. This suggests that while
the effect size of each risk factor may change over time and across
different geographical area, factors that were highly predictive in the
80’s can still help clinicians in correctly stratifying diabetes patients
according to their risk.2. Research design and methods
2.1. DCCT/EDIC data
The DCCT design has been described elsewhere (The Diabetes
Control and Complications Trial Research Group, 1993). Brieﬂy, 1441
Type I diabetes patients (13 to 39 years of age) were enrolled in the
study from 1983 to 1989 and followed, on average, for 6.5 years. The
study was designed as a randomized control trial, with patients
randomly assigned to conventional or intensive insulin therapy. Two
distinct cohort were enrolled: the primary intervention cohort was
composed of patients with albumin concentration ≤ 40 mg/24 h, no
retinopathy and having diabetes for 1 to 5 years, while the secondary
intervention cohort comprises subjects with a longer history of
diabetes (1 to 15 years), mild to moderated non-proliferative diabetic
retinopathy, and albumin excretion rate ≤ 200 mg/24 h. An exhaus-
tive clinical examination was performed at baseline (including
medical history, physical examination, electrocardiogram, and labo-
ratory analyses), while patients’ conditions and risk factors were
re-assessed annually (with glycosylated hemoglobin measured
quarterly (The DCCT Research Group, 1987)).
In 1994, 1394 subjects out of the original 1441 DCCT patients (97%)
accepted to participate in a long term follow-up, the EDIC study, whose
main objective was to collect prospective data on the evolution of
macrovascular and microvascular complications (Epidemiology of
Diabetes Interventions and Complications (EDIC) Research Group,
1999). The EDIC followed the same methods of DCCT, with only minor
modiﬁcations in the schedule of the measurements of glycosylated
hemoglobin (measured annually), fasting lipid levels and renal function
(re-assessed every two years).
For our analyses we selected ﬁfty-one clinical parameters
measured at DCCT baseline (see Table 1 in the Supplementary
Material). These clinical parameters were selected by a panel of
clinical practitioners as the ones commonly used to date in the
treatment of diabetes. Remaining parameters were either measured
solely during the DCCT for research purposes or are not employed in
the clinical practice anymore. This selection was performed in order
to enhance the conformity of our resultswith themedical procedures
followed in modern clinical settings.2.2. Outcomes deﬁnition
We have deﬁned seven different outcomes, each one corresponding
to a severe diabetes-related complication or adverse event. Several
studies (Nathanet al., 2005; TheDiabetesControl andComplicationsTrial
Research Group, 1993, 1995a, 1995b, 1995c, 1995d, 1997) have deﬁned
and studied similar diabetes-related complications on the DCCT/EDIC
data. Whenever possible, we have adopted the same deﬁnitions
suggested by these previous works.
2.2.1. Cardiovascular disease (CVD)
Following the work presented in (Nathan et al., 2005), we deﬁne
CVD as the ﬁrst occurrence of any of the following events: Cardiovas-
cular death, Acute Myocardial Infarction, Bypass graft/Angioplasty,
Angina Pectoris, Cardiac Arrhythmia, Major ECG abnormality, Silent
Myocardial Infarction, Congestive Heart Failure, Transient Ischemic
Attack, Arterial Event requiring surgery.
The relatively young age of the subjects included in the DCCT study
led to a particularly low incidence of CVD events: only twenty-eight
subjects (1.94%) experienced any macro or microvascular complica-
tions. One of the main objectives of the EDIC study was to record and
study the incidence of CVD complications in the DCCT cohort after the
end of the DCCT follow-up. We decided to deﬁne two distinct
outcomes for cardiovascular diseases: the ﬁrst one, hereafter named
CVD-DCCT, takes in consideration the DCCT follow-up and includes
only the CVD events that occurred during the DCCT study; the second
outcome, namely CVD-EDIC, considers the combined follow-up period
of both DCCT and EDIC and includes the CVD events that occurred in
both studies.
2.2.2. Hypoglycemia and ketoacidosis
The Hypoglycemia and Ketoacidosis outcomeswere deﬁned as any
serious hypoglycemic and ketoacidosis event, respectively, requiring
hospitalization, as reported by the patients in each quarterly visit.
2.2.3. Microalbuminuria and proteinuria
Microalbuminuria was deﬁned as albumin/creatinine ratio (ACR)
greater thanor equal to 2.5 mg/mmol (men) or 3.5 mg/mmol (women)
(The National Collaborating Centre for Chronic Conditions, 2008), or
albumin concentration greater than or equal to 20 mg/l, while
Proteinuria was identiﬁed by an albumin/creatinine ratio greater than
or equal to 30 mg/mmol or albumin concentration greater than or equal
to 200 mg/l.
2.2.4. Neuropathy
The Neuropathy outcome was deﬁned as the presence of
abnormalities in the autonomic function. During the DCCT Neurop-
athy was diagnosed on the basis of “physical examination and history
conﬁrmed by unequivocal abnormality of either nerve conduction or
autonomic nervous system” (The Diabetes Control and Complications
Trial Research Group, 1995d). In the CHC validation cohort we used an
alternative deﬁnition based on the presence of dysfunctions in bowel/
bladder or erectile dysfunction.
2.2.5. Retinopathy
The presence and severity of retinopathy were assessed in the
DCCT study according to a scale derived from the Early Treatment
Diabetic Retinopathy Study Scale (ETDRS) (see Tables 1–2 in The
Diabetes Control and Complications Trial Research Group, 1995e).
Currently, the UK Retinopathy Severity (UKRS) scale (The Royal
College of Ophthalmologists, 2012) is usually employed in clinical
practice in UK. We translated the DCCT–ETDRS measurements in
UKRS values, according to the conversion schema reported in Table
1.1 of the Diabetic Retinopathy Guidelines (The Royal College of
Ophthalmologists, 2012) (see also Table 3 in Supplementary Mate-
rial). After the conversion, we adopted an approach similar to (The
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we deﬁned a “retinopathy event” as any worsening in the retina
condition that lasted at least six months.
2.3. Derivation of the computational models and internal validation
The goals of our analyses are (a) identifying the best predictive
signature for each outcome, (b) ﬁtting a computational risk-assessment
model over each signature and (c) assessing the predictive perfor-
mances of these models. The presence of censoring in the DCCT/EDIC
data requires the adoption of specialized methods for achieving these
goals. “Censoring” in these context means that the information about
the outcome can be partial; particularly, the data used in this work are
affected by right-censoring, i.e., for some subjects the exact time-
to-event is not known, and the only available information is that they
were event-free up to a given point (follow-up time).
More formally, the baseline visit of the DCCT data can be
represented as a dataset D containing m = 1441 diabetes patients,
where each patient is represented as a vector of measurements xi
deﬁned over a set of n = 51 risk factors X = {X1,…, Xj,…, Xn}. Each
outcome K is represented by a tuple Ok = {(ti, δi)}, where δi is a binary
variable indicating that subject i experienced the speciﬁc event (δi = 1)
or not (δi = 0),while ti is the recorded time-to-event or follow-up time.
The best signature and predictivemodel for each outcome are indicated
as Xk⁎ ⊆ X andMk, respectively.
SurvivalMax–Min Parent Children (SMMPC, (Lagani & Tsamardinos,
2010)), Lasso Cox Regression (Tibshirani, 1997), Bayesian Variable
Selection (BVS, (Faraggi & Simon, 1998)), and Forward and Univariate
Selection (Bøvelstad et al., 2007) were employed as feature selection
methods for identifying the best performing signatures. These feature
selection methods are based on different theoretical foundations and
assumptions; however, they all attempt to identify a set X* ⊆ X that is
highly predictive with respect to the outcome. Notably, while all
methods try to keep X* parsimonious, only SMMPC provides theoretical
guaranties about retrieving a minimal-size X* (Tsamardinos, Brown, &
Aliferis, 2006).
Once a signatureX* is identiﬁed, predictivemodels can beﬁtted over
it. Cox regression (Cox, 1972), Ridge Cox regression (Van Houwelingen,
Bruinsma, Hart, Van’t Veer, & Wessels, 2006), Accelerated Failure Time
(AFT) models (Kalbﬂeisch & Prentice, 1980), Random Survival Forest
(RSF (Ishwaran, Kogalur, Eugene, & Blackstone, 2008)) and Support
Vector Machine Censored Regression (SVCR, (Shivaswamy, Chu, &
Jansche, 2007)) were employed as regression algorithms for model
ﬁtting. All regressionmethods providemodels that are able to calculate
a single-point risk estimate for any new subject xm + 1, under the form
rm + 1, k = Mk⁎(xm + 1). These estimates can then be used for ranking
patients according to their relative risk. Particularly, for (Ridge) Cox
Regression and AFTmodels the risk estimates are given by ri =∑βjxij,
where β is the coefﬁcient provided by the regression procedure. SVCR
and RSF predictions are given by weighted combinations of kernel-
function products and single survival-tree predictions, respectively.
Each of these feature selection and regression algorithms requires
the user to provide one or more “hyper-parameters”, i.e., parameters
that are not directly estimated from thedata and thatmustbe speciﬁeda
priori. For example, the hyper-parameter λ in the Lasso Cox Regression
regulates the level of shrinkage for the coefﬁcients and, indirectly, the
number of variables to be included in the regression model. SVCR
models require the speciﬁcation of an appropriate kernel function and
cost-parameter C. The hyper-parameters used for each method are
listed in the Supplementary Material.
We employed a complex experimentation protocol in order to (a)
ﬁnd for each outcome the best combination of feature selection and
regression algorithms, along with their respective optimal hyper-
parameters (model selection) and (b) provide an unbiased assessment
of the predictive performance of the selected model (internal
validation/performance estimation). Model selection was performedthrough cross validation. In cross validation, the data are partitioned
in N separate folds, and each fold is in turn held out for performance
estimation purpose (test set) while the rest of the data (training set) is
employed for deriving predictive models. When N is equal to the
number of samples, the procedure is named leave-one-out. The
conﬁguration that obtains the best average performance over the N
folds is then applied on the whole set of data, in order to obtain the
ﬁnal predictive signature X* and the corresponding model M*.
The predictive performances of the ﬁnal models were assessed
through nested-cross validation (Statnikov, Aliferis, Tsamardinos,
Hardin, & Levy, 2005). Nested-cross validation is an extension of the
common cross validation procedure, where an inner loop of cross
validation is performedwithin each training set. The inner loop serves
for selecting the best combination of algorithms and hyper-
parameters, while the N test sets of the outer cross validation are
used exclusively for performance estimation. The procedure provides
a vector P = {P1, …, PN} of estimated performances, whose average
value P is typically taken as single-point estimate. Notably, nested-
cross validation estimates are usually conservative (Tsamardinos,
Lagani, & Rakhshani, 2014). Figs. 1 and 2 in the Supplementary
Material provide a visual representation of both procedures.
All performances are measured in terms of Concordance Index (CI
(Uno, Cai, Pencina, D’Agostino, &Wei, 2011)). The CI metric is speciﬁc
for right censored survival data, and it can be interpreted as the
probability that the model will correctly rank two randomly selected
subjects in accordance to their actual risk of experiencing a given
event. Similarly to the Area Under the Receiver Operator Curve metric
for binary classiﬁcation problems (AUC (Fawcett, 2006)), a value of CI
equals to one indicates a perfect rank in terms of relative risk, while a
value of 0.5 indicates a random ordering.
In both nested and standard cross validation the variables of each
training set are standardized to have zero-mean and unitary standard
deviation. Test sets are standardized according to the mean and
standard deviation values of the corresponding training set. More-
over, categorical variables are transformed in sets of binary variables,
one binary variable for each category. In this way the feature selection
methods are free to include in each model only the categories that are
relevant for the outcome at hand.
2.4. External validation
Validation data were retrospectively collected from 393 diabetes
patients who were admitted at the CHC premises between 2004 and
2014. Forty-nine patients (12.5%) had Type I diabetes, while the
remaining oneswere diagnosedwith Type II diabetes. For each patient
and for each outcome we considered the ﬁrst visit where the risk
factors included in the corresponding predictive signature were
measured. Patients that already developed a speciﬁc complication at
the time of the ﬁrst visit were not employed for the validation of the
respective predictive model. Missing values were replaced with the
average or mode values of the respective predictors, as calculated on
the DCCT baseline data. The data collection procedure produced seven
distinct datasets, one for outcome, with a number of included subjects
ranging between 274 and 343 andwith an average follow-up between
37.6 and 69.4 months. Table 2 in the supplementary material
describes the distribution of the validation data and compares it
with the DCCT cohort.
3. Results
3.1. The predictive signatures and their interplay
The ﬁnal risk assessment models are reported in Table 1. Each
model is composed of a number of risk factors ranging from ﬁve to ten,
for a total of twenty-ﬁve risk factors included in at least one model.
For each outcome a different regression algorithm was chosen by the
Table 1
Risk assessment models.
Clinical parameters CVD-DCCT (Cox
Regression)
CVD-EDIC
(Accelerated
Failure Model)
Hypoglycemia
(Support Vector
Machine)
Ketoacidosis
(Ridge Cox
Regression)
Microalbuminuria
(Random Survival
Forest)
Proteinuria
(Ridge Cox
Regression)
Neuropathy
(Accelerated
Failure Model)
Retinopathy
(Accelerated
Failure Model)
#Models
HbA1c 0.204 23.635 0.0001328 |0.088| 0.15 4.812 0.236 7
Marital Status −0.146
(Never Married)
0.095 (Divorced)
−80.667
(Married)
5.24E-006
(Widowed)
|0.043|
(Married)
−0.26
(Married)
5
Albumin-urine
value (mg/24 h)
0.128 |0.576| 0.178 5.918 4
Age 0.267 37.859 11.394 3
Insulin Regime
(Strict/Standard
control)
380.5 (Strict) |0.054| (Strict) −0.036
(Strict)
3
Retinopathy level
(R0, R1, R2, R3)
|0.091| (R2) 16.113 (R2) 1.437 (R0)
−0.931 (R2)
3
Total Insulin Daily
Dosage (Units/
Weight)
15.707 132.927 0.00013706 3
Post Pubescent
diabetes duration
(in months)
−0.00011212 5.778 0.471 3
Total diabetes
duration (in
months)
|0.062| 0.129 2
Presence of
neuropathy
0.1 0.032 2
Patient’s occupation 0.056 (Manager)
0.074 (Clerical)
0.031 (Laborer)
−0.088 (Student)
−2.61E-005
(Manager)
2
Weight (kg) 0.1 |0.086| 2
Smoke (never/ex-
smoker/current)
−0.114 (Never)
0.128 (Current)
−431.822
(ex-smoker)
2
Patient's body mass
index (kg/m2)
0.096 1
Patient attempted
suicide
0.019 1
Creatinine
Clearance (ml/min)
14.257 1
Family history of
IDDM
−2.07E-005 1
Family History
of NIDDM
−120 1
HDL serum
cholesterol (mg/dl)
−0.1 1
Systolic Blood
Pressure
0.162 1
Past history of
severe
hypoglycemia
141.446 1
Cholesterol (mg/dl) 0.00010094 1
Glomerular ﬁltration
rate (ml/min)
8.98E-005 1
Gender speciﬁc
ideal body weight
−0.00013118 1
Hospitalization(s)
due to ketoacidosis
in past year
0.00011806 1
# Parameters 10 5 5 10 7 6 5 5
Each row represents a risk factor, while each column reports a single model. The header shows the outcome of interest for each model along with the regression algorithm selected
by the model-selection procedure (see the Method section). Cells report model coefﬁcients, with empty cells indicating risk factors not included in the corresponding model.
Categorical risk factors can have multiple coefﬁcients, one for each category included in the model. The semantics of the coefﬁcients depends on the used regression algorithm:
log-hazard ratio for Ridge Cox Regression, survival time multipliers for Accelerated Failure Time models and (linear kernel) Support Vector Machines, relative variable importance
for Random Survival Forest (see text for more details). The original AFT and SVCR coefﬁcients’ signs have been switched in order to have positive values indicating an increase in the
risk in all models. Micro-albuminuria coefﬁcients are reported as absolute values whose signs do not reﬂect an increase or decrease of the risk.
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Ketoacidosis and Proteinuria outcomes, Accelerated Failure Time
models for CVD-EDIC, Neuropathy and Retinopathy, linear-kernel
Support Vector Machines and Random Survival Forest for Hypogly-
cemia and Microalbuminuria, respectively. The corresponding opti-
mal feature selection methods are reported in Supplementary Table 4.
Each regression algorithm produces coefﬁcients with a speciﬁc
interpretation; particularly, Ridge Cox Regression coefﬁcients repre-sent a hazard ratio change in the logarithmic scale. This means that for
a standard-deviation unit increase (i.e., 1.594%, DCCT scale) in
glycated hemoglobin (HbA1c) the hazard of a CVD complication
becomes e0.204 = 1.23 times higher. AFT and linear-kernel SVCR
coefﬁcients act as linear multipliers for the expected time to event.
This means that for the same increase in HbA1c the expected time
before developing Neuropathy decreases by 4.812 months. RSF
usually provides highly non-linear models, where the effect of each
Table 2
Results of the internal and external validation of the models.
Type I Diabetes
Internal Validation
Type I Diabetes
External Validation
Type II Diabetes
External Validation
Model name # Events Average
CI
Cross-Validation
CI Interval
p-value
H0: Aver.
CI ≤ 0.5
# Events CI CI 95%
Conﬁdence
Interval
p-value
H0: CI
≤ 0.5
# Events CI CI 95%
Conﬁdence
Interval
p-value
H0: CI
≤ 0.5
CVD-DCCT 28 0.7257 [0.50962–0.8629] 0.0001 5 0.6887 [0.4923–0.86207] 0.0932 32 0.7143 [0.62384–0.80563] b0.0001
CVD-EDIC 127 0.6204 [0.5549–0.69224] ≤0.0001 5 0.4862 [0.18084–0.81984] 0.5246 33 0.6099 [0.50211–0.71809] 0.0165
Hypoglycemia 408 0.6694 [0.58766–0.75118] ≤0.0001 8 0.6903 [0.5–0.8691] 0.0584 5 0.7002 [0.19012–0.97115] 0.0084
Ketoacidosis 130 0.6745 [0.59412–0.75479] ≤0.0001 3 0.8182 [0.23077–1] 0.0367 – – –
Microalbuminuria 299 0.7421 [0.6751–0.77652] ≤0.0001 6 0.824 [0.66234–0.96875] 0.0078 116 0.5701 [0.52144–0.62193] 0.0058
Proteinuria 44 0.8330 [0.53521–0.96223] ≤0.0001 0 – – – 28 0.6569 [0.53261–0.77125] 0.0027
Neuropathy 149 0.6661 [0.54626–0.74187] ≤0.0001 6 0.735 [0.55102–0.90754] 0.0429 20 0.4359 [0.32132–0.56216] 0.8239
Retinopathy 969 0.6564 [0.60826–0.6745] ≤0.0001 17 0.7201 [0.58669–0.8745] 0.0025 70 0.5451 [0.47399–0.6189] 0.119
External validation was separately performed on Type I and Type II diabetes patients, while internal validation was performed only on Type I patients (as the DCCT study focused
exclusively on Type I diabetes). For the internal validation and for each model (rows) we report the total number of events, the predictive performance expressed as nested-cross
validated Concordance Index (CI), the interval spanned by the CI values obtained in the external loop of the nested-cross validation, and a p-value assessing the null-hypothesis that
the CI is less or equal than 0.5, i.e., that the risk stratiﬁcation provided by the model is not better than random. For the external validations we report the CI values obtained by
applying the ﬁnal models on the external cohorts, along with the 95% conﬁdence interval estimated through bootstrapping. The p-values for the internal evaluation are calculated
through one-tail t-test, while for the external evaluation they are obtained through a permutation-based test (see text for more detail).
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predictors. Consequently, covariates in an RSF model do not have a
univocal coefﬁcient, i.e., it is not generally possible to assess if the factor
has a protective or deleterious effect. However, a method has been
developed for estimating Variable IMPortance (VIMP) in the RSF
models, where the VIMP is proportional to the contribution of the
variable in the predictive performance of the model (Ishwaran, 2007).
The VIMP values for the Microalbuminuria model in Table 1 have been
scaled in order to sum up to one, for ease of comparison.
Given these different interpretations, it is not possible to compare
effect-sizes across different models. However, within each model the
absolute value of each coefﬁcient is directly proportional to the effect
size of the corresponding predictors, and can be used for raking
factors among each other. We further set the signs of all coefﬁcients
such that positive values indicate an increment in risk while negative
values indicate a decrease (except for the VIMP values of the RSF
model that are reported in absolute value).
3.2. Internal and external validation
Table 2 reports and contrasts the results of both internal and
external validation. For the internal validation, we report the average CI
values obtained on the DCCT data through the nested-cross validation
procedure. These values represent our expectations on the perfor-
mances that the models should achieve when applied on a validation
cohort coming from the same population of the training data, i.e., a
hypothetical validation cohort collected in the same years, in the same
geographical area and with similar characteristics of the DCCT data
(Tsamardinos et al., 2014). Models’ results lay in the range [0.6024–
0.8333], meaning that we expect all models to provide a relevant
improvementwith respect to a random ranking the patients (CI = 0.5).
For all models, the CI is statistically signiﬁcantly greater than 0.5
(p-value ≤ 0.001, as calculated with a one-tail t-test). For each model,
we also report the interval spanned by the CI values calculated over the
external folds of the nested-cross validation procedure.
For the external validation, the ﬁnal models were separately
applied on the Type I and Type II diabetes patients of the Chorleywood
cohort. The resulting CI values estimate the predictive ability of the
models on a UK-based population collected in recent times.
Interestingly, the models perform surprisingly well, reaching perfor-
mances statistically signiﬁcantly different from random guessing for
several models. For each model we also report the bootstrapped
estimates (Efron & Tibshirani, 1986) of the 95% conﬁdence interval
and a permutation-based p-value assessing the null hypothesis H0:
CI ≤ 0.5. These permutation p-values are obtained by comparing theobserved CI value with the null-distribution obtained by randomly
permuting 10,000 times the order of the predictions.
For Type I diabetes, severalmodelsmanage to achieve a relevant and
statistically signiﬁcant predictive performance, particularly the Micro-
albuminuria, Neuropathy and Retinopathy models. The CVD-DCCT and
Hypoglycemia are also borderline signiﬁcant. The validation cohorts for
the remaining models contain less than 5 events, and the respective
results should be considered carefully.
The external validation on Type II patients brought positive results
as well. Particularly, both CVD models, as well as the Microalbumi-
nuria and Proteinuria models achieve statistically signiﬁcant results
on a relatively large number of events. The results of the Hypogly-
cemia model are barely signiﬁcant, but it is interesting to note that
this model achieves almost identical results in both Type I and II
external cohorts. The Neuropathy and Retinopathy models did not
prove to be better than random, and the Ketoacidosis model was not
applicable on Type II diabetes patients.3.3. Calibration and re-assessment of the risk models
Risk factors’ effect on the probability of developing diabetes-
related complications may differ across geographical areas or over
time, due to several reasons. For example, the association between a
given risk factor and the outcome may be (partially) mediated by a
third, unknown and unmeasured quantity. If the value of this third
quantity changes across different places, or over time, then also the
association between the risk factor and the outcome changes or even
ceases. It is worthwhile to underline that the DCCT and Chorleywood
cohorts were collected in different countries, and the DCCT data
collection started in 1983, while the earliest recorded visit in Chorley-
wood was performed in 2004 (N20 years difference). Moreover,
treatment options for diabetes patients (Franz et al., 2003; Gallen,
2004) and nutritional habits (Kuklina, Carrol, Shaw, & Hirsch, 2013)
have provably undergone considerable changes during this period.
This implies that themodels derived from the DCCT data may need
to be re-calibrated or revised in order to provide accurate predictions
on the Chorleywood cohorts, since the effects of the risk factors may
differ between the two populations.
We follow the approach suggested by Van Houwelingen (2000) for
assessing the calibration of the single-point risk estimates r against a
known outcome O = {(δi, ti)}. The approach consists in ﬁtting a Cox
regression model h(t|r) = h0(t)exp(α ⋅ r), where h(t|r) is the hazard
at time t given r, h0 is the baseline hazard function, and α is the single
coefﬁcient of the model. A perfectly calibrated model would produce
Table 3
Results of models’ recalibration and re-assessment.
Type I Diabetes
Revised models
Type II Diabetes
Revised Models
Model name # Events Calibrationα Average
CI
Cross-Validation
CI Interval
p-value
H0: Aver.
CI ≤ 0.5
# Events Calibration α Average
CI
Cross-Validation
CI Interval
p-value
H0: Aver.
CI ≤ 0.5
CVD–DCCT 5 0.4989 1 – b0.0001 32 1.2238 0.6757 [0.54386–0.92683] 0.003
CVD–EDIC 5 −0.0011 0.6422 – 0.2712 33 0.0013 0.6621 [0.54348–0.83871] 0.0002
Hypoglycemia 8 0.0015 0.7168 – 0.0284 5 0.0018 0.5867 – 0.3102
Ketoacidosis 3 1502.791 1 – b0.0001 – – – – –
Microalbuminuria 6 0.0975 1 – b0.0001 116 0.0368 0.5932 [0.41146–0.67516] 0.0023
Proteinuria 0 – – – – 28 1.7807 0.7343 [0.55102–0.94286] 0.0002
Neuropathy 6 0.0096 0.6496 – 0.2436 20 –0.0036 0.5285 [0.076923–0.87234] 0.3833
Retinopathy 17 0.6625 0.7521 [0.5–1] 0.0039 70 0.0822 0.5664 [0.42063–0.76238] 0.0381
For each outcome and external cohort, the calibration of the corresponding model is assessed (a) by applying the model on the external cohort and (b) by using the resulting vector
of risk scores ri as a predictor in a Cox regression. Cox coefﬁcients close to one indicate well calibrated models. The predictive capabilities of the selected signatures are then
re-assessed using only the external cohort data. Speciﬁcally, for each outcome and external cohort the predictive performance of the selected signature, regression method and
hyper-parameter conﬁguration is assessed through ten-fold cross-validation. For each model and each cohort the number of events, the calibration Cox regression coefﬁcient α, the
cross-validated CI value along with its corresponding interval over the cross-validation folds are reported. The statistical signiﬁcance of the CI values is assessed through a one-tail
t-test. Outcomes with fewer than 10 recorded events were evaluated with a leave-one-out cross validation schema, which allows better performance estimation.
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estimation or over-estimation of the actual risk, respectively.
Table 3 shows the calibration Cox regression coefﬁcients for each
outcome. The most calibrated models seem to be the ones corre-
sponding to CVD-DCCT, Proteinuria and Retinopathy (the latter on the
Type I cohort only), while all the other models seem to provide
predictions that are somewhat overly optimistic or pessimist. These
results suggest that the models should be revised and re-evaluated on
the new data in order to provide more accurate predictions. We thus
decided to re-ﬁt the coefﬁcients of the models on the external cohorts
and to assess the predictive performances of the revised models
through cross validation. Speciﬁcally, for each outcome and external
cohort we performed a ten-fold cross-validation by using the same
signature, regression method and hyper-parameter conﬁguration select-
ed on the DCCT/EDIC data. For outcomes with fewer than 10 recorded
events we employed a leave-one-out cross-validation schema, and
the performance was calculated on all predictions pooled together.
The adoption of this revision procedure implies that we assume that
the signatures selected on the data from the DCCT baseline visits have
a valuable predictive power also for the Chorleywood cohort.
The results of model revision are reported in Table 3. All the models
showed at least a slight improvement in terms of average CI, except for
the CVD-DCCT and Hypoglycemia models in the Type II diabetes cohort
and for Neuropathy in the Type I cohort. Some models achieve perfect
score (CI = 1), although the limited number of events available for
these outcomes suggests to consider these results carefully.
4. Discussion
4.1. Main ﬁndings
The main contribution of the present work consists of the
derivation of a set of computational models for assessing the risk of
developing diabetes-related complications. The models have been
derived on the basis of the baseline-visit data of the DCCT study and of
the DCCT/EDIC follow-up information. Furthermore, the derivation of
the models led to the identiﬁcation of the minimal-size, maximally
predictive set of features for each considered outcome, out of an initial
set of ﬁfty-one clinical parameters measured in the DCCT baseline
visit. Table 3 reports the clinical parameters included in each risk
assessment model, along with their respective coefﬁcients. Negative
coefﬁcients indicate protective factors, while factors with positive
coefﬁcients are associated with increasing risk.
The level of glycated hemoglobin HbA1c demonstrated to be the
most relevant risk factor, being included in seven models out of eight.Particularly, high values of HbA1c are associatedwith increased risk of
developing diabetes-related complications. This is perfectly in line
with the current literature (Huang, Liu, Moffet, John, & Karter, 2011;
Marcovecchio, Dalton, Chiarelli, & Dunger, 2011; Weber & Schnell,
2009) and in particular with the previous studies on the DCCT cohort
(The Diabetes Control and Complications Trial Research Group, 1996).
Our analyses also point out the relevance of the marital status for
predicting the probability of developing diabetes-related complica-
tions and adverse events. Beingmarried is associatedwith a lower risk
of experiencing hypoglycemia or retinopathy worsening. The pres-
ence of a spouse is known to have a beneﬁcial effect in different
pathologies (Chung, Moser, Lennie, & Riegel, 2006; Goodwin, Hunt,
Key, & Samet, 1987; Sugarman, Bauer, Barber, Hayes, & Hughes, 1993),
and a recent work has demonstrated that, in heart failure patients, this
beneﬁcial effect is mediated by the medication adherence (Wu et al.,
2014). Thus, a possible explanation for our results is that being
married increases the adherence tomedication or diet, and this in turn
improves the patient’s prognosis. For the CVD and Ketoacidosis
models being respectively divorced or widowed increases the risk of
experiencing an adverse event. In this case the marital status may act
as a proxy for the patient’s ages, since both divorced and widowed
DCCT sub-cohorts are characterized by an older age than the rest.
The baseline value of the urine-albumin excretion rate turns out to be
predictive of renal complications (i.e.,Microalbuminuria and Proteinuria),
a result already known in the medical literature (Newman et al., 2005),
and for the development of cardiovascular diseases and Neuropathy.
The CVD-DCCT and CVD-EDIC models are in agreement with the
CVD risk factors previously identiﬁed on the DCCT/EDIC data;
particularly, all elements in the signature of the DCCT-EDIC model
are listed among the clinical characteristics at DCCT baseline that were
signiﬁcantly associated with cardiovascular disease over the course of
the DCCT/EDIC Study (Nathan et al., 2005).
The predictive signatures of both CVD-DCCT and CVD-EDICmodels
closely resemble the results of different studies focusing on
identifying relevant risk factor for cardiovascular complications in
diabetes patients. Particularly, our results are in good agreement with
the results of the UK Prospective Diabetes Study (UKPDS).
The UKPDS was a landmark randomized controlled trial, conduct-
ed over a period of 14 years (1977–1991) and involved 5102 patients
followed, on average, for a period of 10.7 years. The study actually
showed that strict control of blood glucose and blood pressure can
lower the risk of diabetes-related complications in individuals
recently diagnosed with Type II diabetes (Turner & Holman, 1996).
Several risk assessment models were developed on the basis of the
UKPDS data. The ﬁrst UKPDSmodel (Stevens, Kothari, Adler, & Stratton,
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Pressure and Total Cholesterol/HDL Cholesterol ratio as predictors, and
focused on assessing the probability of developing Coronary Hearth
Diseases (CHD). The second version of the model (Clarke et al., 2004)
provides sevendifferentmathematical equations for predicting asmany
diabetes-related complications (stroke, heart failure, fatal or non-fatal
MI, other IHD, amputation, renal failure and blindness) and three
different equations for assessing the risk ofmortality. This secondmodel
is based on the same predictors of the ﬁrst one, but it also includes
information about the patients’ medical history (previous occurrences
of diabetes-related adverse events) and physiology (Body Mass Index,
BMI). The latest version of the UKPDS model was published recently
(Hayes, Leal, Gray, Holman, & Clarke, 2013), and it slightly modiﬁes
the previous versions by including information about micro or
macro-albuminuria, estimated GFR, heart rate, white blood cell count
and hemoglobin.
Interestingly, both our CVD models include a subset of UKPDS
predictors, namely Age, Smoking and HbA1c. The CVD-DCCT model
also includes Systolic Blood Pressure and Weight, both considered in
the latest version of the UKPDS engine. Moreover, our CVD models
and the UKPDS models are fully in agreement regarding the direction
of effect of the common predictors, i.e., all common predictors act as
risk factors, and never as protective factors.
The Hypoglycemia model suggests that being married and having
a family history of non-insulin dependent diabetes have a protective
effect against hypoglycemic events, while a past history of severe
hypoglycemia, strict glucose control and an elevated number of
insulin units per kg of weight signiﬁcantly increase patient’s risk. It is
worthwhile to note that the negative effect of strict glucose control on
the probability of experiencing hypoglycemia was one of the main
outcomes of the DCCT study. In particular, strict glucose control is
known to lower the risk of several diabetes-related complications
except hypoglycemia (The Diabetes Control and Complications Trial
Research Group, 1995a).
The Ketoacidosis model includes several factors, the most relevant
ones being (according to themagnitude of their respective coefﬁcients)
HbA1c, Total Insulin Dosage, Post-Pubescent diabetes duration, Choles-
terol, Hospitalization(s) due to ketoacidosis in past year (risk factors)
and Gender speciﬁc ideal bodyweight (protective factor). To the best of
our knowledge this is the ﬁrst study providing a predictive model for
assessing the risk of experiencing ketoacidosis. Studies investigating the
association of clinical parameters with ketoacidosis exist (Egger, Davey
Smith, Stettler, &Diem, 1997), however they do not provide quantitative
models for the estimation of the risk of ketoacidosis. These studies
generally point out that an intensiﬁed treatment is associated with the
probability of experiencing ketoacidosis, which is in agreement with
our results.
The two models related to renal complications (Microalbuminuria
and Proteinuria) share several predictive factors,whose relevance in the
development of renal complication in diabetes patients is already
known in the literature and was even assessed on the DCCT data
(Lopes-Virella et al., 2013): HbA1c (The Diabetes Control and
Complications Trial Research Group, 1996), Albumin-urine value over
24 h (Newman et al., 2005), Insulin Regime (The Diabetes Control and
ComplicationsTrial ResearchGroup, 1995c) andTotal diabetesduration.
A recent study (Vergouwe et al., 2010) conducted on 1115 Type I
diabetes patients also conﬁrms the relevance of HbA1c and Albumi-
n-urine value for predicting the progression ofmicroalbuminuria, while
another study (Elley et al., 2013) conducted on a large New Zealand
cohort (25,736 Type II diabetes patients) and focusing on End-Stage
Renal Diseases (ESRD) also identiﬁes HbA1c and Total diabetes duration
as relevant risk factors.
The Neuropathy and Retinopathy models also share part of their
predictors, particularly HbA1c, the Retinopathy level at baseline, and
Post-pubescent diabetes duration, all factors that were found to be
associated with low peripheral nerve conduction (an indicator ofneuropathy) in a study of 456 diabetes Type I individuals (Charles
et al., 2010). The association between HbA1c and Retinopathy
progression has been already studied and established (The Diabetes
Control and Complications Trial Research Group, 1995b).
One further relevant contribution of our study is the validation of the
models on the retrospective cohort collected in the ChorleywoodHealth
Center. For the Type I diabetes external cohort, fourmodels out of seven
achieved statistically signiﬁcant (p-value b 0.05) results, while two
models (CVD-DCCT and Hypoglycemia) achieved appreciable CI
performance (0.6887 and 0.6903, respectively), also borderline statis-
tically signiﬁcant. In the case of the Type II diabetes cohort, ﬁve models
out of seven achieved results statistically signiﬁcantly better than
random guessing (CI N 0.5).
Models’ transferability generally increases when the models are
re-calibrated on the new data while the original predictive factors are
conserved. All revised models perform better in terms of CI than the
original models, with the exception of Neuropathy for Type I and
CVD-DCCT/Hypoglycemia for Type II diabetes cohorts. However, we
note that for these models the revised CI values are within the 95%
conﬁdence interval of the CI results of the original models. In general,
these results support our hypothesis that the predictive signatures
selected on the DCCT/EDIC data are able to give accurate predictions
on the cohorts collected in Chorleywood.
4.2. Study limitations
The ﬁrst relevant limitation of this study is the relatively restricted
number of subjects and adverse events in the external validation
cohorts. In some cases the scarcity of recorded events did not allow a
precise estimation of the models’ performances and respective
conﬁdence intervals. Thus, our results only suggest that our models
successfully transfer across populations, but more extensive studies on
larger cohorts of Type I and Type II diabetes patients are needed in order
to gather further evidences.
One more limitation concerns the Hypoglycemia and Ketoacidosis
models. Accurately evaluating the probability of experiencing these
adverse events would require some short-term information about
nutrition and physical activity, not present in the list of considered
predictors. Despite this limitation, both models achieve good level of
predictive performances, in both the internal and external validation.
5. Conclusions
We use the DCCT/EDIC data for deriving a set of computational
models for assessing the risk of developing diabetes-related complica-
tions in diabetes patients. Eachmodel is deﬁned over a parsimonious set
of predictors (clinical parameters) withmaximal predictive power for its
speciﬁc outcome. Predictors included in the models are generally in
agreement with the current literature regarding risk factors for
diabetes-related complications. When applied on a retrospective va-
lidation cohort collected in UK, themodels often provide predictions that
are signiﬁcantly better than random, supporting the hypothesis that the
models transfer on a population that is geographically distant and more
recent than the one originally examined in the DCCT/EDIC studies.
Future works will focus on the validation of the models on larger
cohorts of diabetes patients, both Type I and Type II, in order to further
strengthen the results hereinto presented.
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